Dualitas Therapeutics Signs Bispecific Antibody Discovery Deal With Roche Worth Up to $1 Billion, Including $36.5 Million Upfront
Dualitas Therapeutics announced on Thursday, September 17, 2026 a research collaboration and license agreement with Roche to discover bispecific antibodies for immunology and inflammation diseases. Dualitas receives $36.5 million upfront and can earn research, development, and commercial milestones plus tiered royalties, for a total potential value of up to $1 billion. It will use its DualScreen Bispecific Discovery Engine to functionally screen more than 300,000 novel bispecific combinations, and Roche will handle all later preclinical development, regulatory, manufacturing, and commercial work.